ABTCongressional Stock Trades
Abbott Laboratories
Pharmaceutical Preparations
Congressional stock trades in Abbott Laboratories (ABT) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
51
Politicians Trading
20
Last Traded
Oct 2, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Markwayne MullinR | Jan 31, 2025 | Jan 8, 2025 | Sell | $1,001 - $15,000 | -3.58% |
Page 2 of 2
Price History
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
20 members of Congress have disclosed 51 trades in Abbott Laboratories (ABT). Most active: Ro Khanna (8), Josh Gottheimer (6), Gilbert Ray Cisneros, Jr. (5).
Across all disclosures, members of Congress reported 20 purchases and 31 sales of Abbott Laboratories (ABT). The most recent trade was on Oct 2, 2026.
Gilbert Ray Cisneros, Jr. disclosed buying Abbott Laboratories (ABT) on Sep 18, 2026, valued at $1,001 - $15,000.
Pete Sessions disclosed selling Abbott Laboratories (ABT) on Oct 2, 2026, valued at $50,001 - $100,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.